Aurinia Pharmaceuticals (NASDAQ:AUPH) Price Target Cut to $13.00

Aurinia Pharmaceuticals (NASDAQ:AUPHGet Rating) (TSE:AUP) had its target price dropped by equities researchers at Oppenheimer from $15.00 to $13.00 in a research report issued to clients and investors on Monday, Stock Target Advisor reports. The brokerage currently has an “outperform” rating on the biotechnology company’s stock. Oppenheimer’s price target indicates a potential upside of 59.90% from the company’s previous close.

Several other analysts have also commented on the stock. Royal Bank of Canada cut their target price on shares of Aurinia Pharmaceuticals from $22.00 to $18.00 and set an “outperform” rating for the company in a research note on Friday, August 5th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Aurinia Pharmaceuticals in a research note on Thursday, April 28th. StockNews.com upgraded Aurinia Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, May 23rd. Finally, HC Wainwright cut their price objective on Aurinia Pharmaceuticals from $33.00 to $30.00 in a report on Wednesday, May 4th. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $20.40.

Aurinia Pharmaceuticals Price Performance

AUPH stock opened at $8.13 on Monday. Aurinia Pharmaceuticals has a 12 month low of $7.70 and a 12 month high of $33.97. The firm has a market cap of $1.15 billion, a PE ratio of -7.01 and a beta of 0.95. The firm has a 50 day simple moving average of $10.49 and a 200 day simple moving average of $12.09.

Aurinia Pharmaceuticals (NASDAQ:AUPHGet Rating) (TSE:AUP) last released its earnings results on Thursday, August 4th. The biotechnology company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.03). Aurinia Pharmaceuticals had a negative net margin of 178.32% and a negative return on equity of 38.01%. During the same quarter last year, the business earned ($0.37) EPS. As a group, sell-side analysts expect that Aurinia Pharmaceuticals will post -0.7 earnings per share for the current year.

Hedge Funds Weigh In On Aurinia Pharmaceuticals

Institutional investors have recently bought and sold shares of the stock. Tcwp LLC bought a new position in shares of Aurinia Pharmaceuticals in the first quarter worth about $25,000. Total Clarity Wealth Management Inc. bought a new position in shares of Aurinia Pharmaceuticals in the second quarter worth about $26,000. Nisa Investment Advisors LLC bought a new position in shares of Aurinia Pharmaceuticals in the second quarter worth about $34,000. Geneos Wealth Management Inc. increased its stake in shares of Aurinia Pharmaceuticals by 54.2% in the first quarter. Geneos Wealth Management Inc. now owns 3,250 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 1,142 shares during the period. Finally, Lazard Asset Management LLC bought a new position in shares of Aurinia Pharmaceuticals in the fourth quarter worth about $45,000. 33.09% of the stock is currently owned by institutional investors.

About Aurinia Pharmaceuticals

(Get Rating)

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis.

See Also

Stock Target Advisor logo

Analyst Recommendations for Aurinia Pharmaceuticals (NASDAQ:AUPH)

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.